Dimerix Limited (AU:DXB) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Dimerix Limited has announced the successful completion of a fifth scheduled review by the Independent Data Monitoring Committee (IDMC) for its Phase 3 ACTION3 kidney trial, with no safety concerns reported. The trial will continue as planned, reinforcing the strong safety profile of their DMX-200 treatment for FSGS kidney disease. This development brings hope to patients with limited treatment options.
For further insights into AU:DXB stock, check out TipRanks’ Stock Analysis page.